Document:

Employment Agreement between Jane Houldsworth El Naggar and Cancer Genetics

 Exhibit 10.19 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (this
“Agreement”) is entered into on December 23, 2011, effective as of January 1, 2012 (“Effective Date”), by and between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and Jane Houldsworth El
Naggar Ph.D. (“Employee”). 
 In consideration of the mutual covenants and conditions set forth herein, and other good
and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 1.
Employment. The Company hereby employs Employee in the capacity of the Vice President, Research and Development of the Company, reporting directly to the President & Chief Executive Officer of the Company (the “CEO”).
Employee accepts such employment and agrees to perform such roles and provide such management and other services for the Company as are customary to such office and such additional responsibilities, consistent with her position as the Company’s
Vice President, Research and Development, as may be assigned to her from time to time by the CEO. All employees in the research and development department of the Company shall report, directly or indirectly, to Employee, and Employee shall make (or
delegate to others) all employment decisions regarding and with respect to her direct and indirect reports. 
  

	2.	Term. 

 2.1 The
employment hereunder shall be for a period commencing on January 1, 2012 (the “Commencement Date”) and ending on December 31, 2012 (the “Initial Term”), unless earlier terminated as provided in Section 4 or 5. This
Agreement shall be automatically renewed for successive one-year periods thereafter, commencing upon the expiration of the Initial Term, unless earlier terminated as provided in Section 4 or 5. Employee’s employment following the
Commencement Date will be on a full-time business basis requiring the devotion of substantially all of her productive business time for the efficient and successful operation of the business of the Company. 

 

	3.	Compensation and Benefits 

3.1 Cash Compensation. For the performance of Employee’s duties hereunder following the Commencement Date, the Company shall
pay Employee an annual salary in the amount of $200,000 or such greater amount as may be determined by the Board of Directors of the Company (the “Base Compensation”). The annual salary shall be paid in installments either every two weeks
or twice per month, based on and in accordance with Company’s regular payroll procedures. 
  

	 	3.2	Bonus Plan. 

 (a)
Employee shall be entitled to participation in the bonus compensation plan further defined in Section 3.2(b). Additional detail of the bonus compensation plan will be provided in written detail to Employee once the bonus compensation plan is
adopted by the Board, which will occur within a reasonable time after the Commencement Date. Any bonus or incentive compensation paid to Employee shall be in addition to Base Compensation. 

(b) Employee shall be eligible annually for a bonus to be determined by the Board of up to Twenty-five Percent (25%) of Base
Compensation. The amount of the bonus shall be determined by the Board, based on its reasonable assessment of Employee’s performance and the Company’s performance against appropriate goals established annually by the Board or the
Compensation Committee of the Board after consultation with the CEO, prior to the beginning of the period of time from which the 

  
 1 

 
performance of the Employee would be evaluated and measured for such bonus. If all such goals are achieved for a given period, the amount of the bonus will be up to Twenty-five Percent
(25%) of Base Compensation for that period. Employee’s bonus, as earned, shall be payable at the end of the first fiscal quarter of the company following the end of the period for which the bonus was earned. The first bonus period shall be
for the last 6 months of fiscal 2011 (with a 12.5% of Base Compensation maximum). Thereafter, the bonus plan period shall be the Company fiscal year. 
  

	 	3.3	Stock Options and Restricted Stock Grant. 

 (a) From time to time the Company may grant to Employee options under the Company’s 2008 Stock Option Plan (or its successor stock plan) to purchase shares of the Company’s common stock at a
stated exercise price per share. 
 (b) The Company granted to Employee two (2) incentive stock options under the 2008
Stock Option Plan to purchase an aggregate of 81,000 shares of Common Stock vesting in accordance with the notices of stock option grant and stock option grants dated January 19, 2010 (the “Incentive Stock Options”). 

3.4 Benefits. Employee and her dependents shall be entitled to such medical/dental, disability and life insurance coverage and
such 401(k) plan and other retirement plan participation, vacation, sick leave and holiday benefits, if any, and any other benefits as are made available either to Company’s other senior executives or to the Company’s personnel generally,
all in accordance with the Company’s benefits program in effect from time to time. The Employee is responsible for paying the employee’s portion of the benefit costs consistent with other relevant employees of the Company. The
medical/dental, disability and life benefits provided to Employee under this Section 3.4 shall continue until, and shall terminate, six (6) months after a Termination Event pursuant to Section 4 or Section 5 hereof, except to the
extent that Employee receives comparable benefits at a future employer during the six (6) months after the Termination Event, in which case the pertinent benefits from the Company shall end upon Employee’s enrollment in the future
employer’s benefit plan. 
 3.5 Reimbursement of Expenses. Employee shall be entitled to be reimbursed for all
reasonable expenses including the cost of travel for business; home office operation; cell phone, Blackberry, business meals and entertainment, incurred by Employee in performing her tasks, duties and responsibilities under Sections 2.1 and 2.2 or
otherwise in connection with and reasonably related to the furtherance of the Company’s business. Employee shall submit expense reports and receipts documenting the expenses incurred in accordance with Company policy. 

 

	4.	Change of Control. 

 4.1
In the event of a termination of Employee’s employment hereunder by the Company with or without Cause or by Employee with or without Good Reason, within 12 months following a Change of Control, the Company will promptly pay Employee, in lieu of
the amounts required under Section 5.2(b) and in addition to the amounts required under Sections 3.4, 3.5 and 5.2(a), a severance amount, payable in a lump sum on the 60th day following the date of such termination of employment provided that
Employee has executed, delivered and not revoked a Release in the form attached as Exhibit A (whether or not executed by the Company), equal to twelve (12) months base compensation, plus an amount equal to the prior year bonus. 

4.2 As used herein, a “Change of Control” of the Company shall mean either of the following: (i) the acquisition by any
person(s) (individual, entity or affiliated or unaffiliated group) in one or a series of transactions (including, without limitation, issuance of shares by the Company or 

  
 2 

 
through merger of the Company with another entity) of direct or indirect record or beneficial ownership of more than 50% of the voting power with respect to matters put to the vote of the
shareholders of the Company and, for this purpose, the terms “person” and “beneficial ownership” shall have the meanings provided in Section 13(d) or 14(d) of the Securities Exchange Act of 1934 or related rules promulgated
by the Securities and Exchange Commission; or (ii) a sale of all or substantially all of the assets of the Company. Notwithstanding the foregoing, the following acquisitions shall not constitute a “Change of Control”: (1) any
capital raised by the Company (not used for a redemption of outstanding shares); (2) the closing of any transaction that in good faith may be reasonably characterized as an acquisition of another entity by the Company rather than the other way
around; or (3) any acquisition of the Company or its shares by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company. 

 

	5.	Termination 

 5.1
Termination Events. The employment hereunder will terminate upon the occurrence of any of the following events (“the Termination Event”): 
 (a) Employee dies; or 
 (b) The Company, by written notice to Employee or her
personal representative, discharges Employee due to the inability to continue to perform the duties previously assigned to Employee hereunder prior to such injury, illness or disability for a continuous period exceeding 90 days or 180 out of 360
days by reason of injury, physical or mental illness or other disability, which condition has been certified by a physician reasonably acceptable to the Company; provided, however, that prior to discharging Employee due to such disability, the
Company shall give a written statement of findings to Employee or her personal representative setting forth specifically the nature of the disability and the resulting performance failures, and Employee shall have a period of thirty (30) days
thereafter to respond in writing to the Company’s findings, whereupon the Company shall conduct a reasonable and fair hearing with the Employee and any supporting witnesses and evidence for the Employee to reach a final determination; or

 (c) Employee is discharged by the Company for “Cause”. As used in this Agreement, the term “Cause” shall
mean: 
 (i) Employee’s final and unappealed conviction of (or pleading guilty or “nolo contendere” to) any
felony or a major misdemeanor involving dishonesty or moral turpitude; provided, however, that prior to discharging Employee for Cause, the Company shall give a written statement of findings to Employee setting forth specifically the grounds on
which Cause is based, and Employee shall have a period of ten (10) days thereafter to respond in writing to the Company’s findings; or 
 (ii) The Employee’s (1) unreasonable failure to perform her duties, as determined by the Board of Directors, or (2) substantial and material breach of, or default under, this Agreement or
the Proprietary Information and Invention Assignment Agreement (as defined herein). The unreasonable failure of the Company, as determined by the Board of Directors, to meet reasonable benchmarks, as may be agreed to from time to time by the
Employee and the Board of Directors. In the case of any of the conditions set forth in this Section 5.1(c)(ii), the Employee shall be given written notice of the intent of the Board of Directors to terminate the Employee’s employment under
this paragraph, and shall be permitted thirty (30) days from receipt of such written notice to promptly cure any such breach or default to the reasonable satisfaction of the Board of Directors. 

  
 3 

 (d) Employee is discharged by Company other than in accordance with Section
5.1(a)-(c) (a termination “without Cause”), which the Company may do at any time, with at least thirty (30) advance written notice, subject to the full performance of the obligations of the Company to the Employee pursuant to
Section 4 or Section 5.2, as the case may be; or 
 (e) Employee voluntarily terminates her employment due to
“Good Reason”, which shall mean (i) a material default by the Company in the performance of any of its obligations hereunder, which default remains uncured by the Company for a period of thirty (30) days following receipt of
written notice thereof to the Company from Employee; (ii) a material diminution of the roles, responsibilities or duties and/or the position, title or authority of Employee hereunder; or (iii) a requirement that Employee report to any
person(s) other than the CEO or the Chairman of the Board; or 
 (f) Employee voluntarily terminates her employment without Good
Reason, which Employee may do at any time with at least 30 days advance notice. 
  

	5.2	Effects of Termination. 

 (a) Upon termination of Employee’s employment hereunder for any reason, the Company will promptly pay Employee all Base Compensation owed to Employee and all bonuses earned, as previously defined in
writing by the Company, and unpaid through the date of termination (including, without limitation, salary and employee expenses reimbursements). Employee shall be paid for any performance bonus plan then in effect on a pro rata basis for that period
of time during the fiscal year in which termination occurs at the time normally scheduled for payment as provided in Section 3.2(b), but such amount, if any, shall only be paid to the extent other employees are paid their bonus amounts at such
time. 
 (b) Unless Section 4 applies (in which case Section 4, and not this Section 5.2(b), will be followed),
and in addition to the amounts required under Sections 3.4, 3.5 and 5.2(a): 
 (i) Upon termination of Employee’s
employment under Sections 5.1(a), Company shall continue to pay the Base Compensation to the estate of the Employee for a period of ninety (90) days after such death. 
 (ii) Upon termination of Employee’s employment under Section 5.1(b), the Company shall pay Employee, commencing immediately upon such termination of employment, monthly amounts equal to the then
applicable Base Compensation, excluding bonus, for a period of twelve (12) months after termination. 
 (iii) Upon
termination of Employee’s employment under Section 5.1(d) or 5.1(e), the Company shall pay Employee, commencing on the 60th day following the date of such termination of employment provided that Employee has executed, delivered and
not revoked a Release in the form attached as Exhibit A (whether or not executed by the Company), monthly amounts equal to the then applicable Base Compensation, excluding bonus, for a period of six (6) months after termination. 

(c) Upon termination of Employee’s employment hereunder pursuant to Sections 5.1(b), 5.1(c), Employee agrees that for the twelve
(12) month period following the Termination Event, further upon termination of Employee’s employment hereunder pursuant to Sections 5.1(d), 5.1(e) or 5.1(f), Employee agrees that for the six (6) month period following the
Termination Event: 
 (i) Employee will not directly, whether as an individual, employee, director, consultant or advisor, or
in any other capacity whatsoever other than a passive investor, provide services 

  
 4 

 
to any person, firm, corporation or other business enterprise which is involved in the business of development, marketing or providing a diagnostic service offering of CGH microarrays for
hematologic and urogenital diseases (“Competitive Engagements”), unless Employee obtains the Company’s prior written consent. 
 (ii) Employee will not knowingly, directly and actively solicit any individual to leave the Company’s then full-time employ, for any reason, to join or be employed by any employer that then employs
Employee as an employee, director, consultant or advisor. 
 (iii) Employee will not knowingly, directly and actively induce
any provider, agent, customer, supplier, distributor, or licensee of the Company to cease doing business with the Company or to breach its agreement with the Company. 
 (d) Employee acknowledges that monetary damages may not be sufficient to compensate the Company for any economic loss, which may be incurred by reason of breach of the restrictive covenants set forth in
Section 5.2(c). Accordingly, in the event of any such breach, the Company shall, in addition to any remedies available to the Company at law, be entitled to seek equitable relief in the form of an injunction, precluding Employee from continuing
to engage in such breach. 
 (e) If any restriction set forth in Section 5.2(c) is held to be unreasonable, then Employee
and the Company agree, and hereby submit, to the reduction and limitation of such prohibition to such area or period as shall be deemed reasonable. 
 (f) Except as required by law, Employee agrees not to make to any person, including but not limited to customers of the Company, any statement that disparages the Company or which reflects negatively upon
the Company, including but not limited to statements regarding the Company’s financial condition, its officers, directors, shareholders, employees and affiliates. The Company agrees not to make to any person, including but not limited to
customers of the Company, any statement that disparages Employee or which reflects negatively upon Employee, including but not limited to statements regarding her financial condition. 

 

	6.	Conflicts of Interest 

6.1 Duty to Disclose. Employee will provide the CEO and Board with a report on the existence of any actual conflicts of interest.
In connection with any actual conflicts of interests, Employee will confidentially disclose the existence of any conflicts of interests, including her financial interest and the minimum about of facts necessary to assess the conflict of interest, to
the CEO and Board or to any special committees with Board delegated powers considering the proposed transaction or arrangement. If the Board or committee has reasonable cause to believe that Employee has failed to disclose any actual conflict of
interest, it shall inform Employee of the basis for such belief and afford Employee an opportunity to explain the alleged failure to disclose. 
 6.2 Determining Whether a Conflict of Interest Exists. After disclosure of the financial interest and the minimum about of facts necessary to assess the conflict of Interest, and after any
discussion with the Employee, Employee shall excuse herself from the Board or committee meeting while the determination of whether a conflict of interest exists is discussed and voted upon. The remaining Board or committee members shall determine
whether a conflict of interest exists. Notwithstanding the foregoing, however, prior approval of the Board of Directors shall not be required if the transaction falls below a de minimis threshold established by the Board. 

  
 5 

 6.3 Addressing Conflict. If the Board determines that Employee has an actual conflict
of interest, the Company and Employee shall employ good faith actions to resolve the conflict of interest. 
  

	7.	General Provisions 

 7.1
Assignment. Neither party may assign or delegate any of her or its rights or obligations under this Agreement without the prior written consent of the other party. 
 7.2 Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all prior written and verbal agreements
between the parties. 
 7.3 Modifications. This Agreement may be changed or modified only by an agreement in writing
signed by both parties hereto. 
 7.4 Successors and Assigns. The provisions of this Agreement shall inure to the benefit
of, and be binding upon, the Company and its successors and permitted assigns and Employee and Employee’s legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person shall
have become a party to this Agreement and have agreed in writing to join and be bound by the terms and conditions hereof. 
 7.5
Governing Law. This Agreement shall be governed by, construed and enforced in accordance with, the laws of the State of New Jersey, and venue and jurisdiction for any disputes hereunder shall be heard in any court of competent jurisdiction in
New Jersey for all purposes. 
 7.6 Severability. If any provision of this Agreement is held by a court of competent
jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nevertheless continue in full force and effect. 
 7.7 Further Assurances. The parties will execute such further instruments and take such further actions as may be reasonably necessary to carry out the intent of this Agreement. 

7.8 Notices. Any notices or other communications required or permitted hereunder shall be in writing and shall be deemed received
by the recipient when delivered personally or, if mailed, five (5) days after the date of deposit in the United States mail, certified or registered, postage prepaid and addressed, in the case of the Company, to its corporate headquarters,
attention CEO, and in the case of Employee, to the address shown for Employee on the signature page hereof, or to such other address as either party may later specify by at least ten (10) days advance written notice delivered to the other party in
accordance herewith. 
 7.9 No Waiver. The failure of either party to enforce any provision of this Agreement shall not
be construed as a waiver of that provision, nor prevent that party thereafter from enforcing that provision of any other provision of this Agreement. 
 7.10 Legal Fees and Expenses. In the event of any disputes under this Agreement, each party shall be responsible for their own legal fees and expenses which it may incur in resolving such dispute,
unless otherwise prohibited by applicable law or a court of competent jurisdiction. 
 7.11 Counterparts. This Agreement
may be executed by exchange of facsimile signature pages and/or in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. 

  
 6 

 7.12 Insurance on Employee. The Company shall be entitled to obtain and maintain, at
the Company’s expense, key person life insurance on the life of the Employee, naming the Company as the beneficiary of such policy. Employee agrees to cooperate with the Company and take all reasonable actions necessary to obtain such
insurance, such as taking usual and customary physical examinations and providing true and accurate personal, health related information for any application at no cost to Employee. 

7.13 Company Directors & Officers Insurance. The Company shall maintain in good standing a standard D&O policy for a
minimum of $3Mn USD (Three Million USD) which the Employee has the right to review. 
 7.14 Tax Withholding. The Company
may withhold from any benefit provided or payment due hereunder the amount of withholding taxes due any federal, state or local authority in respect of such benefit or payment and may take such other action as may be necessary to satisfy all
obligations for the payment of such withholding taxes. 
 7.15 Section 409A Compliance. 

(a) Notwithstanding the foregoing, if necessary to comply with the restriction in Section 409A(a)(2)(B) of the Internal Revenue Code
of 1986, as amended (the “Code”) concerning payments to “specified employees,” any payment on account of Employee’s separation from service that would otherwise be due hereunder within six months after such separation shall
nonetheless be delayed until the first business day of the seventh month following Employee’s date of termination and the first such payment shall include the cumulative amount of any payments that would have been paid prior to such date if not
for such restriction. For purposes of this provision, Employee shall be a “specified employee” for the 12-month period beginning on the first day of the fourth month following each “Identification Date” if she is a “key
employee” (as defined in Section 416(i) of the Code without regard to Section 416(i)(5) thereof) of the Company at any time during the 12-month period ending on the “Identification Date.” For purposes of the foregoing, the
Identification Date shall be December 31. 
 (b) This Agreement is intended to comply with the requirements of
Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a
manner so that no payments due under this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code. For purposes of Section 409A, each payment made under this Agreement shall be treated as
a separate payment. In no event may Employee, directly or indirectly, designate the calendar year of payment. Notwithstanding anything contained herein to the contrary, Employee shall not be considered to have terminated employment with the Company
for purposes of Sections 4 and 5 hereof unless she would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii). An event shall not be considered to
be a Change of Control for purposes of payment of an amount or benefit under this Agreement unless such event is also a “change in control event” within the meaning of Section 409A. 

(c) All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A,
including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Employee’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for
reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the
year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. 

  
 7 

 7.16 Proprietary Information and Invention Assignment Agreement. The terms of the
proprietary information and invention assignment agreement attached hereto as Exhibit B (the “Proprietary Information and Invention Assignment Agreement”) are incorporated herein by reference. If there is any conflict between the terms of
the Proprietary Information and Invention Assignment Agreement and the terms of this Agreement, the terms of this Agreement shall prevail. 
 [Signature Page To Follow] 

  
 8 

 IN WITNESS WHEREOF, the Company and Employee have executed this Agreement, effective as of
the day and year first above written. 
  

			
		 	CANCER GENETICS, INC.:
		
	By:	 	/s/ Panna Sharma
		 	Name: Panna Sharma
		 	Title: Chief Executive Officer
		
		 	EMPLOYEE:
		
		 	/s/ Jane Houldsworth El Naggar
		 	Jane Houldsworth El Naggar Ph.D.

 Address: 400 Pulis Avenue, Franklin Lakes, NJ 07417 

  
 9Consulting Agreement with Equity Dynamics, Inc

 Exhibit 10.38 
 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (the “Agreement”), effective as
of August 1, 2010, is entered into by Cancer Genetics, Inc., a Delaware corporation with its principal place of business at 201 State Route 17, Rutherford, New Jersey 07070 (the “Company”), and Equity Dynamics, Inc. (the
“Consultant”). 
 WHEREAS, pursuant to an oral agreement between the parties, the Consultant has been providing
consulting services to the Company since August 2010 and the Company has been paying the Consultant a monthly retainer of $10,000 plus expenses for such consulting services; 
 WHEREAS, the parties now desire to memorialize the terms of their agreement; 
 NOW THEREFORE, in
consideration of the mutual covenants and promises set forth herein, the Company and the Consultant hereby agree as follows: 
  

	 	1.	Consulting Services. The Company hereby retains the Consultant, and the Consultant hereby agrees, to provide to the Company consulting and advisory services (the
“Services”) related to the Company financing strategies, including on-going assistance with financing contacts, and other business consulting requirements as they arise. 

 

	 	2.	Compensation. In consideration for the Services, the Company hereby agrees to pay the Consulting a $10,000 retainer each month for Services rendered. In
addition, the Company will reimburse the Consultant for all reasonable expenses incurred in connection with the Services provided. 

  

	 	3.	Termination. Either party may terminate this Agreement at any time without cause upon thirty (30) days notice to the other party. 

 

	 	4.	Freedom to Contract. Consultant represents and warrants that the Consultant (including its officers, directors, employees and affiliates) is not bound by any
agreement or arrangement with or duty to any other person that would conflict with this Agreement. 

  

	 	5.	Confidential Information. 

  

	 	a.	 Definition of Confidential Information. “Confidential Information” shall mean means all of the trade secrets, know-how, ideas,
business plans, pricing information, the identity of and any information concerning customers or suppliers, computer programs (whether in source code or object code), procedures, processes, strategies, methods, systems, designs, discoveries,
inventions, production methods and sources, marketing and sales information, information received from others that the Company is 

	 	
obligated to treat as confidential or proprietary, and any other technical, operating, financial and other business information that has commercial value, relating to the Company, its business,
potential business, operations or finances, or the business of the Company’s affiliates or customers, of which the Consultant may have acquired or developed knowledge or of which the Consultant may in the future acquire or develop knowledge of
during the course of providing Services to the Company. 

  

	 	b.	Protection of Confidential Information. The Consultant (including its officers, directors, employees and affiliates) will use the Confidential Information only
in the performance of the Services under this Agreement. Consultant (including its officers, directors, employees and affiliates) will not disclose the Confidential Information, directly or indirectly, at any time during or after the termination of
this Agreement except to persons authorized by the Company to receive this information. The Consultant (including its officers, directors, employees and affiliates) will not use the Confidential Information, directly or indirectly, at any time
during or after the termination of this Agreement, for the personal benefit of any of the officers, directors, employees or affiliates of the Consultant, for the benefit of the Consultant or any other person or entity, or in any manner adverse to
the interests of the Company. Consultant (including its officers, directors, employees and affiliates) will take all action reasonably necessary to protect the Confidential Information from being disclosed to anyone other than persons authorized by
the Company. The Consultant represents and warrants that Consultant has entered into agreements with its officers, directors, employees and affiliates which contain confidentiality obligations at least as protective of the Company’s
Confidential Information as those contained herein. 

  

	 	c.	Return of Confidential Information. When this Agreement is terminated, Consultant will immediately return or destroy all materials (including without limitation,
written or printed documents, email and computer disks or tapes, whether machine or user readable, computer memory, and other information reduced to any recorded format or medium) containing, summarizing, abstracting or in any way relating to the
Confidential Information. 

  

	 	6.	Indemnification. The Company shall indemnify the Consultant, its officers, directors and employees (the “Indemnified Parties”) against all judgments,
fines, settlement payments and expenses, including reasonable attorneys’ fees, paid or incurred in connection with any claim, action, suit or proceeding, whether civil or criminal, to which an Indemnified Party be made a party or with which
Consultant may be threatened by reason of his having been a Consultant to the Company. No indemnification shall be made hereunder (a) with respect to any such action, suit or proceeding where it shall be finally adjudicated that the Indemnified
Party did not act in good faith and in the reasonable belief that his or her action was in the best interest of the Company or (b) as otherwise prohibited by law. 

	 	7.	Assignment. The rights and obligations under this Agreement may not be assigned or delegated by the Consultant. 

 

	 	8.	Amendment and Waiver. Neither this Agreement nor any term, covenant, condition or other provision hereof may be changed, waived or discharged except by an
instrument in writing signed by the party against which enforcement of the change, waiver or discharge is sought. 

  

	 	9.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey. 

 

	 	10.	Entire Agreement. This Agreement embodies the entire agreement between the Company and the Consultant, and, except as otherwise expressly provided herein, this
Agreement shall not be affected by reference to any other document. 

  

	 	11.	Notices. Any notice required or permitted to be given under this Agreement shall be deemed delivered when given by registered or certified mail addressed to the
party to whom such notice is give at the address of such party set forth above or at such address as such party may provide to the other in writing from time to time. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

 

			
	EQUITY DYNAMICS, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Date:	 	 
	
	CANCER GENETICS, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]